Suppliers / 3D Imaging Drug Design and Development

3D Imaging Drug Design and Development

United States Updated 9 July 2026

3D Imaging Drug Design and Development is an API manufacturer based in United States. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 13 June 2025 as OAI.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
3
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 13 June 2025 OAI US FDA
  • 31 January 2024 VAI US FDA
  • 20 April 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Little Rock, United States 3009143510

What they file, and where

Molecule Regulators Docs
Clofarabine US FDA 1

Also appears on these molecule pages

Clofarabine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 3 None

Questions about 3D Imaging Drug Design and Development

Does 3D Imaging Drug Design and Development hold a US DMF or a CEP?
3D Imaging Drug Design and Development holds 1 active US drug master file. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is 3D Imaging Drug Design and Development FDA-registered?
One site operated by 3D Imaging Drug Design and Development carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did 3D Imaging Drug Design and Development's last inspection go?
The most recent inspection on record closed on 13 June 2025 as OAI (Official Action Indicated, the worst classification: objectionable conditions were found and regulatory action was warranted). 3 inspections are on file, of which 1 closed as OAI.
Where does 3D Imaging Drug Design and Development manufacture?
1 registered site is on record, in United States (Little Rock). Every site is listed on this page with the register it came from.
What does 3D Imaging Drug Design and Development make?
1 molecule is on record against 3D Imaging Drug Design and Development, including Clofarabine. Each links through to that molecule's full manufacturer list.
Where does 3D Imaging Drug Design and Development file?
Filings are on record with US FDA, 3 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. 3D Imaging Drug Design and Development comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was OAI, on 13 June 2025.

Comparable suppliers

MSN Laboratories shares 1 molecule Alembic Pharmaceuticals shares 1 molecule Olon shares 1 molecule Matrix Pharmacorp shares 1 molecule Biophore India Pharmaceuticals shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability